Proposal of 'reactive-lymphocyte/histiocyte rich large B-cell lymphoma' as an alternate term for 'nodular lymphocyte predominant Hodgkin lymphoma' that would also address its overlap with T-cell/histiocyte rich large B-cell lymphoma [0.03%]
将“结节性淋巴细胞为主霍奇金淋巴瘤”的替代术语定为“反应性淋巴细胞/组织细胞丰富的大B细胞淋巴瘤”,同时也解决了它与T细胞/组织细胞丰富的大B细胞淋巴瘤的重叠问题
Kikkeri N Naresh
Kikkeri N Naresh
Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study [0.03%]
口服化疗药物治疗复发难治淋巴瘤的姑息治疗:一项多中心回顾研究
Simon J Bulley,Anna Santarsieri,Isabel C Lentell et al.
Simon J Bulley et al.
PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is an orally administered daily chemotherapy regimen used with palliative intent in relapsed refractory lymphoma. To our knowledge, no data on PEP-C have been reported since...
Lymphoid morphology, hyperviscosity and extensive immunoglobulin deposits in myeloma [0.03%]
骨髓瘤的淋巴样形态,高粘度及广泛的免疫球蛋白沉积
Tushar Sehgal,Nicholas Lafferty,Linda Barton et al.
Tushar Sehgal et al.
A new aberrantly spliced BCR-ABL1 transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemia [0.03%]
慢性粒细胞白血病患者常规监测中应用不同的实时定量逆转录聚合酶链反应技术发现新的异常剪接的BCR-ABL1转录本变异(e13a1)
Nicole Naumann,Ulrike Bross-Bach,Wolfgang Seifarth et al.
Nicole Naumann et al.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) of BCR-ABL1 transcript level is an essential part of routine disease monitoring in patients with chronic myeloid leukemia. One patient sample (e13a2 transcript detected ...
Diffuse large B-cell lymphoma with phenotype switch, anaplastic features and aberrant T-cell marker expression during disease evolution [0.03%]
疾病发展过程中表现表型转换、多形性特点及异常T细胞标记表达的弥漫大B细胞淋巴瘤
Xiaoqiong Wang,Pei Lin,Jie Xu et al.
Xiaoqiong Wang et al.
Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL-variant [0.03%]
经典毛细胞白血病(HCL)和变异体HCL的反向相蛋白阵列(RPPA)蛋白质分析
Fieke W Hoff,Tiara L Griffen,Yihua Qiu et al.
Fieke W Hoff et al.
Classical hairy cell leukemia (HCL-c) and HCL variant (HCL-v) are recognized as separate entities with HCL-v having significantly shorter overall survival. Proteomic studies, shown to be prognostic in various forms of leukemia, have not bee...
Down syndrome-associated transient abnormal myelopoiesis with placental involvement [0.03%]
与唐氏综合症相关的伴有胎盘受累的暂时性异常髓系增生
Yahya Daneshbod,Ravi Raghavan
Yahya Daneshbod
Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia [0.03%]
慢粒白血病基础上出现JAK2阳性的骨髓纤维化一例
Christopher Gerard Mullen,Victoria Louise Campbell,Tamasin Doig et al.
Christopher Gerard Mullen et al.
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database [0.03%]
复发性多发性骨髓瘤患者的卡非佐米使用模式及结果:加拿大骨髓瘤研究组(CMRG)数据库的多机构报告
Arleigh McCurdy,Martha Louzada,Christopher P Venner et al.
Arleigh McCurdy et al.
Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relap...
Lawrence J Jennings
Lawrence J Jennings
Current guidelines recommend that Acute Myeloid Leukemia (AML) patients with NPM1 mutations should be monitored for measurable residual disease by quantifying the transcripts and normalizing them to ABL1 transcripts. In this short report, a...